Chronic Hepatitis B Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Gilead, Arbutus, Vir Biotechnology, Antios, Ascletis, Qilu, Ascentage, GSK, Janssen, Henlix, Enyo, Vaxine, Vaccitech, Nucorion, Enanta, VenatoRx

The Chronic Hepatitis B Market size in the 7MM is approximately USD 1,500 million in 2022 and is projected to increase during the forecast period (2023-2032). As per DelveInsight, the Chronic Hepatitis B Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of new therapies in the market.

DelveInsight's "Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Hepatitis B Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Chronic Hepatitis B therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Hepatitis B treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Chronic Hepatitis B: An Overview
Hepatitis B is a potentially life-threatening and one of the most common liver infections caused by the hepatitis B virus (HBV), which attacks and injures the liver. A hepatitis B infection can result in either an acute or chronic infection.

If an individual suffers from an HBV infection that lasts more than 6 months, the infection becomes chronic. Chronic hepatitis B (CHB) increases the risk of developing liver failure, liver cancer, or cirrhosis. The risk of developing a CHB infection is also directly related to the age at which one first becomes exposed to the hepatitis B virus. HBV is mainly transmitted through exposure to infected blood and bodily fluids. It can be transmitted to others through direct contact with blood, unprotected sex, illegal drugs, and unsterilized or contaminated needles.

In highly endemic areas, HBV is spread primarily from mother to child at birth (perinatal transmission), or through horizontal transmission (exposure to infected blood), especially from an infected child to an uninfected child during the first 5 years of life. The development of chronic infection is very common in infants infected by their mothers or before 5 years.

Chronic Hepatitis B Market Key Facts
• The market size in the 7MM will increase at a CAGR of 24% due to increasing awareness of the disease and WHO initiatives and the launch of the emerging therapy aiming at a functional cure.
• Among EU4, Germany accounts for the maximum market size in 2022, while Spain occupies the bottom of the ladder in 2022.
• By 2032, among all the emerging therapies, the highest revenue will be generated by the bepirovirsen + peginterferon a2a combination in the 7MM.
• The total prevalent cases of Chronic Hepatitis B in the 7MM comprised approximately 56,333,000 cases in 2022 and are projected to decrease during the forecast period
• The total prevalent cases of Chronic Hepatitis B in the United States were around 22,56,700 cases in 2022.
• In the United States, approximately 55% of the patient share is attributed to males, whereas around 40% of females suffer from Chronic Hepatitis B.
• Among the EU4, Germany accounted for the largest number of Chronic Hepatitis B cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• According to DelveInsight estimates, there were around 3,04,900 and 53,800 cases of compensated and decompensated liver in Japan in 2022. These cases are projected to increase during the forecast period.

Get a Detailed Overview of the Evolving Chronic Hepatitis B Market Trends @
https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Hepatitis B Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Hepatitis B therapies in the market. It also provides a detailed assessment of the Chronic Hepatitis B market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Chronic Hepatitis B drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Chronic Hepatitis B Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Hepatitis B Epidemiology
The epidemiology section covers detailed insights into the historical, and current Chronic Hepatitis B patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Chronic Hepatitis B Epidemiology Segmented as -
• Total Prevalent Cases of Chronic Hepatitis B
• Total Diagnosed Prevalent Cases of Chronic Hepatitis B
• Gender-specific Diagnosed Prevalent Cases of Chronic Hepatitis B
• Age-specific Diagnosed Prevalent Cases of Chronic Hepatitis B
• Type-specific Diagnosed Prevalent Cases of Chronic Hepatitis B
• Total Treated Cases of Chronic Hepatitis B in the 7MM

Get Key Insights Into the Evolving Chronic Hepatitis B Epidemiology Trends @
https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Hepatitis B Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Hepatitis B market or expected to be launched during the study period. The analysis covers the market share by Chronic Hepatitis B drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Chronic Hepatitis B Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Chronic Hepatitis B Market @
https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Hepatitis B Therapeutics Assessment
CHB infection is treated with either interferon or oral antiviral agents. These treatments are expected to slow the progression of cirrhosis, reduce the incidence of liver cancer, and improve long-term survival. Among antiviral agents, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide (TAF) are recommended as the first choice of treatment regimens. Liver transplantation may be considered in cases of chronic liver failure.

The hepatitis B vaccine is given as a series of three or four injections administered over 6 months. The first dose of the vaccine is sometimes called the birth dose since it is frequently given within the first 24 h of birth. The vaccine is 90-95% effective in preventing hepatitis B. Additionally, the WHO advises using prophylaxis and immunization to stop the mother-to-child transmission of hepatitis B. Implementing safer sex practices and blood safety measures also helps prevent transmission.

Several major pharma and biotech companies are developing therapies for Chronic Hepatitis B Virus Infection. Currently, Ligand Pharmaceuticals is leading the therapeutics market with its Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage of clinical development.

Leading Companies in the Chronic Hepatitis B Therapeutics Market Include
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and many others

Emerging and Marketed Chronic Hepatitis B Therapies Covered in the Report Include
• Pradefovir: Ligand Pharmaceuticals
• PBGENE-HBV: Precision Biosciences
• SBT8230: Silverback Therapeutics
• VIR-3434: Vir Biotechnology
• RG6346:Dicerna Pharmaceuticals
• RG7854: Roche
And many more

Learn More About the Emerging Therapies and key Companies in the Chronic Hepatitis B Therapeutics Market @
https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Hepatitis B Competitive Intelligence Analysis
4. Chronic Hepatitis B Market Overview at a Glance
5. Chronic Hepatitis B Background and Overview
6. Chronic Hepatitis B Patient Journey
7. Chronic Hepatitis B Epidemiology and Patient Population
8. Chronic Hepatitis B Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Hepatitis B Unmet Needs
10. Key Endpoints of Chronic Hepatitis B Treatment
11. Chronic Hepatitis B Marketed Products
12. Chronic Hepatitis B Emerging Therapies
13. Chronic Hepatitis B Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Hepatitis B Market Outlook (7 major markets)
16. Chronic Hepatitis B Access and Reimbursement Overview
17. KOL Views on the Chronic Hepatitis B Market.
18. Chronic Hepatitis B Market Drivers
19. Chronic Hepatitis B Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Functional Electrical Stimulation (FES) Devices Market
https://www.delveinsight.com/report-store/functional-electrical-stimulation-fes-devices-market

Hypoactive Sexual Desire Disorder Market
https://www.delveinsight.com/report-store/hypoactive-sexual-desire-disorder-hsdd-market

Complicated Intra-Abdominal Infections Market
https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market

Malignant Pleural Mesothelioma (MPM) Market
https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market

Mitochondrial Myopathies Market
https://www.delveinsight.com/report-store/mitochondrial-myopathies-market

Asthma Diagnostic Devices Market
https://www.delveinsight.com/report-store/asthma-diagnostic-devices-market

Mayus Kinase (jak) Inhibitors Market
https://www.delveinsight.com/report-store/mayus-kinase-inhibitors-market

Acute Heart Failure Market
https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market

Bacterial Vaginosis Market
https://www.delveinsight.com/report-store/bacterial-vaginosis-market

Hyperphosphatemia Market
https://www.delveinsight.com/report-store/hyperphosphatemia-market

Pleural Effusion Market
https://www.delveinsight.com/report-store/pleural-effusion-market

Epidermolysis Bullosa Market
https://www.delveinsight.com/report-store/epidermolysis-bullosa-market

Gestational Diabetes Market
https://www.delveinsight.com/report-store/gestational-diabetes-market

Intratumoral Cancer Therapies Market
https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market

Wasting Syndrome Market
https://www.delveinsight.com/report-store/wasting-syndrome-market

Parkinson's Disease Related Dementia Market
https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market

Vagus Nerve Stimulator (VNS) Global Market
https://www.delveinsight.com/report-store/vagus-nerve-stimulator-market

Abetalipoproteinemia Market
https://www.delveinsight.com/report-store/abetalipoproteinemia-market

Myelofibrosis (MF) Market
https://www.delveinsight.com/report-store/myelofibrosis-mf-market

Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market

Homozygous Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market

Partial Onset seizures Market
https://www.delveinsight.com/report-store/partial-onset-seizures-market

West Nile Encephalitis Market
https://www.delveinsight.com/report-store/west-nile-encephalitis-market

Gonorrhea Market
https://www.delveinsight.com/report-store/gonorrhea-market

Polymyositis Market
https://www.delveinsight.com/report-store/polymyositis-market

Subarachnoid Hemorrhage Market
https://www.delveinsight.com/report-store/subarachnoid-hemorrhage-market

Acute Pancreatitis Market
https://www.delveinsight.com/report-store/acute-pancreatitis-market

Acute Respiratory Distress Syndrome (ARDS) Market
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market

PARP Inhibitors Market
https://www.delveinsight.com/report-store/parp-inhibitors-competitive-landscape-pipeline-and-market-analysis

Bacterial Conjunctivitis Market
https://www.delveinsight.com/report-store/bacterial-conjunctivitis-market

Desmoplastic Small Round Cell Tumors (DSRCTS) Market
https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market

Hemophilia with Inhibitor Market
https://www.delveinsight.com/report-store/hemophilia-with-inhibitor-market

Pelvic Inflammatory Disease Market
https://www.delveinsight.com/report-store/pelvic-inflammatory-disease-market

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market

PCSK9 Inhibitors Market
https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market

Dravet Syndrome Market
https://www.delveinsight.com/report-store/dravet-syndrome-market

Genital Warts Market
https://www.delveinsight.com/report-store/genital-warts-condyloma-acuminatum-market

Orthopedic Trauma Devices Market
https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market

Acute Lymphoblastic Leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market

Erythema Market
https://www.delveinsight.com/report-store/erythema-market

Primary Open Angle Glaucoma (POAG) Market
https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-market

Cutaneous Lupus Erythematosus Market
https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-market

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market
https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market

Traumatic Brain Injury Assessment Devices Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-assessment-management-devices-market

Cartilage Diseases Market
https://www.delveinsight.com/report-store/cartilage-diseases-market

Hormone Sensitive Advanced Prostate Cancer Market
https://www.delveinsight.com/report-store/hormone-sensitive-advanced-prostate-cancer-market

Neuromodulation Devices Global Market
https://www.delveinsight.com/report-store/neuromodulation-devices-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.